McAllister K H
Sandoz Research Institute Berne Ltd., Berne, Switzerland.
Eur J Pharmacol. 1996 Oct 31;314(3):307-11. doi: 10.1016/s0014-2999(96)00576-6.
The present studies investigated whether SDZ 220-581 ((S)-alpha-amino 2'chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid), a potent, competitive antagonist at the NMDA glutamate receptor subtype, reversed haloperidol-induced catalepsy in rats, a widely used model of Parkinson's disease. SDZ 220-581 (0.32-3.2 mg/kg i.p.) dose- and time-dependently reduced the time spent in an abnormal position induced by haloperidol (1.0 mg/kg s.c.). Compared to other NMDA receptor antagonists the rank order of potency was MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine) > SDZ 220-581 > SDZ EAA 494 (D-CPPene: (S)-(E)-4-(3-phosphonoprop-2-enyl)-piperazine-2-carboxylic acid) > SDZ EAB 515 ((S)-alpha-amino-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid). Since it has been demonstrate that SDZ 220-581 counters the effects of L-dihydroxyphenylalanine (L-DOPA) on the motor disturbances of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-pre-treated primates, the results suggest that the reversal of haloperidol-induced catalepsy by competitive NMDA receptor antagonists may not be predictive of efficacy in other models of Parkinson's disease.
